Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > Cancer Supportive Care Drugs Market

Cancer Supportive Care Drugs Market Size

Report ID: GMI6489
Published Date: Aug 2023
Report Format: PDF

Download Free Sample

Cancer Supportive Care Drugs Market Size

Cancer Supportive Care Drugs Market size was estimated to be USD 14.4 billion in 2022 and is predicted to increase at a growth rate of 1.9% till 2032. Progress in cancer treatments like chemotherapy, radiation therapy, targeted therapy, and immunotherapy has elevated treatment effectiveness. Prioritizing the well-being of cancer patients has gained significant prominence in cancer care.

To get key market trends

Download Free Sample

The rise in awareness and education, the aging demographic, the growing inclination towards personalized medicine, and the growing population of cancer survivors have collectively emphasized the management of long-term treatment-related effects.

Moreover, the increasing global incidence and prevalence of cancer contribute to a growing patient population that requires supportive care. According to American Cancer Society, Inc. over 1.9 million new cancer cases is expected to be diagnosed in the U.S. in 2023. As more individuals are diagnosed with cancer, the demand for effective supportive care drugs to manage treatment-related side effects also rises.

Cancer Supportive Care Drugs Market Report Attributes
Report Attribute	Details
Base Year:	2022
Cancer Supportive Care Drugs Market Size in 2022:	USD 14.4 Billion
Forecast Period:	2023 to 2032
Forecast Period 2023 to 2032 CAGR:	1.9%
2032 Value Projection:	USD 17.3 Billion
Historical Data for:	2018 to 2022
No. of Pages:	121
Tables, Charts & Figures:	218
Segments covered:	Drug Class, Cancer Type, Distribution Channel, and Region
Growth Drivers:	Rising incidence and prevalence of cancer Increasing technological advancements in cancer therapies Rising geriatric population Growing integration of digital health Increasing awareness among patients and healthcare professionals about the availability and benefits of supportive care drugs
Pitfalls & Challenges:	Availability of alternative therapies or complementary treatments Limited healthcare resources Adverse effect drugs

Learn more about the key segments shaping this market

Download Free Sample

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Global market for cancer supportive care drugs was worth USD 14.4 billion in 2022 and is estimated to expand at 1.9% CAGR from 2023-2032 attributed to the growing progress in cancer treatments, such aschemotherapy, radiation therapy, targeted therapy, and immunotherapy.

The G-CSFs (granulocyte-colony stimulating factors) segment accounted for 22.8% share in the cancer-supportive care drugs market owing to its extensive usage to avoid neutropenia.

Asia Pacific industry is set to witness 2.3% CAGR from 2023-2032 and reach USD 6.1 billion by 2032 driven by the rising incidence of cancer due to population growth, aging, changing lifestyles, and environmental factors.

Some of the top companies in the industry are Amgen, Inc., Merck & Co., Inc., Johnson & Johnson Services, Inc., Heron Therapeutics, Inc., Novartis AG, GSK plc, F. Hoffmann-La Roche Ltd., Helsinn Healthcare SA, Teva Pharmaceuticals Industries Ltd., and Fagron Group.